Browse
 
Dahl Chase Folders

FISH for MET Gene Amplification

Reference Number: AA-00435


 

SECTION EIGHT

Dahl-Chase Diagnostic Services

MOLECULAR PATHOLOGY TESTING

FISH FOR MET GENE AMPLIFICATION

 

Clinical Significance:

 

Non small-cell lung carcinoma (NSCLC) accounts for approximately 85% of lung cancers.  Targeted therapies based on genetic alterations in the tumor are appropriate for selected cases, currently principally in non-squamous NSCLC.  Identifying of mutations in oncogenes associated with NSCLC, physicians can distinguish patients who are more likely to benefit from certain therapies, such as tyrosine kinase inhibitors (TKI) erlotinib and gefitinib in case of EGFR mutation or critozinib in case of MET gene amplification. 

 

The presence of MET gene amplification in patients with NSCLC defines a subset of individuals that may be responsive to small-molecule kinase inhibitors, such as critozinib. 

 

Specimen Requirements and Collection:

Formalin fixed tissue containing a sufficient amount of tumor (generally at least several mm of tumor tissue submitted in the tissue block

 

Forms:

Molecular Pathology requisition form

 

Transport:

Send paraffin block containing tumor at room temperature

 

Reference Range:

 

MET gene amplification present = positive result

MET gene amplification no detected = negative result

 

CPT codes:

88377

 

 

Test reported:

Results are reported within 7-10 days